Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 8/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 7/20 | 1.00 |
| ▸ | PIM1 | P11309 | 6/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.67 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.67 |
| ▸ | ABL1 | P00519 | 2/20 | 0.58 |
| ▸ | GSK3A | P49840 | 4/20 | 0.48 |
| ▸ | HPGDS | O60760 | 2/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL456747 | 0.95 | PIK3CD (0.91) | GSK3BPIK3CDPIK3CBPIM1PIK3CA | |
| SCHEMBL2166013 | 0.92 | PIK3CD (0.84) | GSK3BPIK3CDPIK3CBPIM1PIK3CA | |
| SCHEMBL456195 | 0.90 | PIK3CD (0.81) | GSK3BPIK3CDPIK3CBPIM1PIK3CA | |
| SCHEMBL457518 | 0.89 | PIK3CD (0.79) | GSK3BPIK3CDPIK3CBPIM1PIK3CA | |
| SCHEMBL458879 | 0.88 | PIK3CD (0.78) | GSK3BPIK3CDPIK3CBPIM1PIK3CA | |
| SCHEMBL456663 | 0.84 | PIK3CD (0.72) | GSK3BPIK3CDPIK3CBPIM1PIK3CA | |
| SCHEMBL12405717 | 0.84 | PIK3CD (0.72) | GSK3BPIK3CDPIK3CBPIM1PIK3CA | |
| SCHEMBL13578870 | 0.84 | PIK3CD (0.72) | GSK3BPIK3CDPIK3CBPIM1PIK3CA | |
| SCHEMBL458468 | 0.84 | PIK3CD (0.72) | GSK3BPIK3CDPIK3CBPIM1PIK3CA | |
| SCHEMBL1119169 | 0.82 | PIK3CD (0.77) | GSK3BPIK3CDPIK3CBPIM1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280705-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2014-10-08 | — | — | EP | claimed |
| EP-1751088-B1 | OXO-SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-10-08 | — | — | EP | claimed |
| US-20110183973-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2011-07-28 | — | — | US | claimed |
| EP-2280705-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2011-02-09 | — | — | EP | claimed |
| WO-2009147189-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | claimed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| EP-2280705-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| EP-2280705-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-8536169-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2013-09-17 | — | — | US | disclosed |
| US-8536169-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2013-09-17 | — | — | US | disclosed |
| EP-2613781-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| US-20110183973-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2011-07-28 | — | — | US | disclosed |
| US-20110183973-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2011-07-28 | — | — | US | disclosed |
| US-20110183973-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2011-07-28 | — | — | US | disclosed |
| EP-2280705-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009147189-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009147189-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | GSK3B 389/4885PIK3CD 2938/4885PIK3CB 1706/4885 |
| US-20110183973-A1 | Novel Compounds | PIK3C2B, PIK3CD, PIK3CA | GSK3B 56/4885PIK3CD 2/4885PIK3CB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.